With rare reverse merger, Florida firm sidesteps into limelight

24 May 2023

While financial experts may debate the merits and demerits of the initial public offering (IPO), it’s not the only way to take a company public.

With a drought of IPOs and waning investor confidence amid economic uncertainty, Florida-based cancer company Morphogenesis has opted for a less common route to market, merging with the Nasdaq-listed mitochondrial specialist CohBar (Nasdaq: CWBR).

The tie-up will bring new scientific and professional expertise into the group, and comes with a $15 million private fundraise on the part of CohBar, giving an anticipated cash runway through to the end of next year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK